Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies

被引：104

作者：

Dragovich, PS ^{[1
]}

Webber, SE ^{[1
]}

Babine, RE ^{[1
]}

Fuhrman, SA ^{[1
]}

Patick, AK ^{[1
]}

Matthews, DA ^{[1
]}

Lee, CA ^{[1
]}

Reich, SH ^{[1
]}

Prins, TJ ^{[1
]}

Marakovits, JT ^{[1
]}

Littlefield, ES ^{[1
]}

Zhou, R ^{[1
]}

Tikhe, J ^{[1
]}

Ford, CE ^{[1
]}

Wallace, MB ^{[1
]}

Meador, JW ^{[1
]}

Ferre, RA ^{[1
]}

Brown, EL ^{[1
]}

Binford, SL ^{[1
]}

Harr, JEV ^{[1
]}

DeLisle, DM ^{[1
]}

Worland, ST ^{[1
]}

机构：

[1] Agouron Pharmaceut Inc, San Diego, CA 92121 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 1998年 / 41卷 / 15期

关键词：

D O I：

10.1021/jm980068d

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The structure-based design, chemical synthesis, and biological evaluation of peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds incorporate various Michael acceptor moieties and are shown to irreversibly bind to HRV serotype 14 3CP with inhibition activities (k(obs)/[I]) ranging from 100 to 600 000 M-1 s(-1). These inhibitors are also shown to exhibit antiviral activity when tested against HRV-14-infected H1-HeLa cells with EC50's approaching 0.50 mu M. Extensive structure-activity relationships developed by Michael acceptor alteration are reported along with the evaluation of several compounds against HRV serotypes other than 14. A 2.0 Angstrom crystal structure of a peptide-derived inhibitor complexed with HRV-2 3CP is also detailed.

引用

页码：2806 / 2818

页数：13

共 72 条

[51] A GLUTAMIC-ACID SPECIFIC SERINE-PROTEASE UTILIZES A NOVEL HISTIDINE TRIAD IN SUBSTRATE-BINDING [J].